Xiaojun Chen
Clinical trials sponsored by Xiaojun Chen, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a simpler lymph node check replace major surgery for endometrial cancer? Results expected Jan 2027 (estimated)
-
Hormone blockers and letrozole tested to spare uterus in early endometrial cancer
Disease control Recruiting nowResearchers are testing a combination of a gonadotropin-releasing hormone agonist injection and the drug letrozole in obese women with early-stage endometrial cancer that has not responded to progestin. The goal is to see if this hormone-blocking approach can shrink tumors and al…
Phase 2/3 • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Hormone combo tested as Fertility-Sparing option for early uterine cancer
Disease control Recruiting nowResearchers test whether a combination of GnRHa and letrozole can shrink early endometrial cancer or atypical hyperplasia in non-obese patients who have not responded to progestin therapy. The trial compares this regimen with Diane-35 plus metformin. About 80 participants receive…
Phase 2/3 • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can weight management plus hormones reverse precancerous uterine changes and preserve fertility?
Disease control Recruiting nowThis study is for overweight or obese women aged 18–45 with atypical endometrial hyperplasia, a precancerous condition of the uterine lining. Participants will receive either a levonorgestrel-releasing IUD (Mirena) or megestrol acetate pills, combined with a weight management pro…
Phase 2/3 • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC